Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?-Reference-Cited by-同舟云学术

Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?

Published:2022-08 Issue: Volume:171 Page:25-42
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Corti Chiara^ORCID,Antonarelli Gabriele^ORCID,Valenza Carmine,Nicolò Eleonora,Rugo Hope,Cortés Javier,Harbeck Nadia,Carey Lisa A.,Criscitiello Carmen,Curigliano Giuseppe^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference100 articles.

1. Histology-agnostic drug development - considering issues beyond the tissue;Pestana;Nat Rev Clin Oncol.,2020

2. New approach to cancer therapy based on a molecularly defined cancer classification;Cortés;CA Cancer J Clin.,2014

3. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine;Seligson;Clin Pharmacol Ther.,2021

4. First FDA approval agnostic of cancer site - when a biomarker defines the indication;Lemery;N Engl J Med.,2017

5. Dostarlimab: first approval;Markham;Drugs. Jul,2021

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

2. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer;Journal of Clinical Oncology;2024-07-10

3. Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker;Targeted Oncology;2024-07-04

4. Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?;Expert Opinion on Biological Therapy;2023-11

5. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread;Cancer Treatment Reviews;2023-11